Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-02-21
2006-02-21
Russel, Jeffrey Edwin (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C514S006900, C514S008100, C514S021800, C514S034000, C530S410000, C530S411000, C536S006400
Reexamination Certificate
active
07001991
ABSTRACT:
A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate comprises an anti-cancer drug and a targeting protein, wherein said anti-cancer drug is selected from the group consisting of heat sensitizers, photosensitizers and apoptosis inducing compounds, a method for making such a conjugate, and methods for using the conjugate. The targeting protein is preferably transferrin.
REFERENCES:
patent: 4886780 (1989-12-01), Faulk
patent: 4895714 (1990-01-01), Faulk
patent: 5000935 (1991-03-01), Faulk
patent: 5087616 (1992-02-01), Myers et al.
patent: 5108987 (1992-04-01), Faulk
patent: 5208323 (1993-05-01), Page et al.
patent: 5238940 (1993-08-01), Liu et al.
patent: 5268165 (1993-12-01), Hedlund et al.
patent: 5326778 (1994-07-01), Rosebrough
patent: 5688488 (1997-11-01), Low et al.
patent: 5906977 (1999-05-01), Sinn et al.
patent: 6310039 (2001-10-01), Kratz
patent: 6548531 (2003-04-01), Breimer et al.
patent: 2002/0137901 (2002-09-01), Cavanaugh
patent: 2004/0204339 (2004-10-01), DiMartino
patent: WO 98/10794 (1998-03-01), None
patent: WO 00/66090 (2000-11-01), None
patent: WO 02/00170 (2002-01-01), None
patent: WO 02/091991 (2002-11-01), None
patent: WO 02/091992 (2002-11-01), None
patent: WO 02/092116 (2002-11-01), None
patent: WO 03/004559 (2003-01-01), None
patent: WO 03/032899 (2003-04-01), None
Hamblin et al., “Photosensitizer targeting in photodynamic therapy. I. Conjugates of haematoporphyrin with albumin and transferrin.”, Journal of Photochemistry and Photobiology. B: Biology, 1994, vol. 26, pp. 45-56.
Database CA 'Online!, Chemical Abstracts Service, “Trials of molecular targeting to overcome multidrug resistance”. Database accession No. 2000:151715, abstract, (2000).
Berczi et al., “Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cells”, Archives of Biochemistry and Biophysics, 300(1), 356-63 Coden: ABBIA4: ISSN: 003-9861, 1993.
Hoshino et al., “Receptor-binding, in vitro cytotoxicity, and in vivo distribution of transferrin-bound cis-platinum (II) of differing molar ratios”, Journal of Controlled Release, vol. 37, No. 1, Nov. 1995, pp. 75-81.
Faulk WP and Johnson PM. Immunological studies of human placentae. Identification and distribution of proteins in mature chorionic villi. Clin Exp Immunol 1977; 27: 365-375.
Faulk WP, Johnson PM, Dorling J and Temple A. Non-specific factors of resistance in human placentae. Prot Biol Fluids 1976; 24: 139-142.
Johnson PM and Faulk WP. Immunological studies of human placentae: Identification and distribution of proteins in immature chorionic villi. Immunology 1978; 34: 1027-1035.
Faulk WP and Galbraith GMP. Trophoblast transferrin and transferrin receptors in the host-parasite relationship of human pregnancy. Proc R Soc Lond B 1979; 204: 83-97.
Hsi BL, Yeh CJG and Faulk WP. Human amniochorion: Tissue-specific markers, transferrin receptors and histocompatibility antigens. Placenta 1982; 3: 1-12.
Yeh CJG, Hsi BL and Faulk WP. Histocompatibility antigens, transferrin receptors and extra-embryonic markers of human amniotic epithelial cells in vitro. Placenta 1983; 4: 361-368.
Galbraith GMP, Galbraith RM and Faulk WP. Transferrin binding by human lymphoblastoid cell lines and other transfomed cells. Cell Immunology 1980; 49: 215-222.
Faulk WP, Hsi BL and Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. Lancet 1980; ii: 390-392.
Yeh CJG, Taylor C and Faulk WP. Transferrin binding by peripheral blood mononuclear cells in human lymphomas, myelomas and leukamias. Vox Sanguinis 1984; 46: 217-223.
Faulk WP, Harats H and Berczi A. Transferrin receptor growth control in normal and abnormal cells. In:Oxidoreduction at the Plasma Membrane. vol. 1. (eds., FL Crane, JD Morre and H Low) CRC Press, Boca Raton, FL, 1990; pp. 205-224.
Yang DC, Wang F, Elliot RL and Head JF. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. Anticancer Res 2001; 21: 541-549.
Barnett D, Wilson GA, Lawrence AC and Buckley GA. Transferrin receptor expression in the leukaemias and lymphoproliferative disorders. Clin Lab Haematol 1987; 9: 361-70.
Whitney JF, Clark JM, Griffin TW, Gautam S and Leslie KO. Transferrin receptor expression in nonsmall cell lung cancer. Histopathologic and clinical correlates. Cancer 1995; 76: 20-25.
Recht L, Torres CO, Smith TW, Raso V and Griffin TW. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg 1990; 72: 941-945.
Sciot R, Paterson AC, van Eyken P, Callea F, Kew MC and Desmet VJ. Transferrin receptor expression in human hepatocellular carcinoma: an immunohistochemical study of 34 cases. Histopathol 1988; 12: 53-63.
Seymour GJ, Walsh MD, Lavin MF, Strutton G and Gardiner RA. Transferrin receptor expression by human bladder transitional cell carcinomas. Urol Res 1987; 15: 341-344.
Lindholm ML, Lindberg LA, Vilja P, Puolakka VM, Nordling S, Schroder T and Schroder J. Expression of the human transferrin receptor in subrenal capsule assay in the mouse. J Surg Oncol 1988; 38: 57-62.
Hereiz HA and Bayoumi FA. Evaluation of diagnosis of ovarian malignancy using immunohistochemical technique. J Egyptian Public Hlth Assoc 1992; 67: 697-707.
Medeiros LJ, Picker LJ, Horning SJ and Warnke RA. Transferrin receptor expression by non-Hodgkin's lymphomas. Correlation with morphologic grade and survival. Cancer 1988; 61: 1844-1851.
Soyer HP, Smolle J, Torne R and Kerl H. Transferrin receptor expression in normal skin and in various cutaneous tumors. J Cutaneous Pathol 1987; 14: 1-5.
Lesley J, Hyman R, Schulte R and Trotter J. Expression of transferrin receptor on murine hematopoietic progenitors. Cell Immunol 1984; 83: 14-25.
Testa U, Pelosi E and Peschle C. The transferrin receptor. Crit Rev Oncogen 1993; 4: 241-276.
Bothwell TA, Charlton RW, Cook JD and Finch CA.Iron Metabolism in Man, Blackwell Scientific, Oxford, 1979.
Ponka P and Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999; 31: 1111-1137.
Hamilton TA, Gray PW and Adams DO. Expression of the transferrin receptor on murine peritoneal macrophages is modulated by in vitro treatment with interferon gamma. Cell Immunol 1984; 89: 478-488.
Byrd TF and Horowitz MA. Interferon gamma-activated human monocytes downregulate transferrin receptors and inhibits the intracellular multiplication ofLegionella. pneumophilaby limiting the availability of iron. J Clin Invest 1989; 83: 1457-1465.
Kronke M, Leonard W, Depper JM and Greene WC. Sequential expression of genes involved in human T lymphocyte growth and differentiation. J Exp Med 1985; 161: 1593-1598.
Galbraith RM and Galbraith GM. Expression of transferrin receptors on mitogen-stimulated human peripheral blood lymphocytes: relation to cellular activation and related metabolic events. Immunology 1983; 133: 703-710.
Neckers LM and Cossman J. Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. Proc Nat Acad Sci USA 1983; 80: 3494-3498.
Testa U, Kuhn L, Petrini M, Quaranta MT, Pelosi E and Peschle C. Differential regulation of iron regulatory element-binding protein(s) in cell extracts of activated lymphocytes versus monocytes-macrophages. J Biol Chem 1991; 266: 3925-3930.
Sieser C, Texieira S and Kuhn LC. Interleukin-2-dependent transcriptional and post-transcriptional regulation of transferrin receptor mRNA. J Biol Chem 1993; 268: 13,074-13,080.
Neckers LM, Yenokida G and James SP. The role of the transferrin receptor in human B lymphocyte activation. J Immunol 1984; 133: 2437-2441.
Neckers LM and Trepel JB. Transferrin receptor expression and the control of cell growth. Cancer Invest 1986; 4: 461-470.
Yeh CJG, Papamichail M and Faulk WP. Loss of transferrin receptors following induced differentiation of HL-60 promyelocytic leukemia cells. Exper Cell Res 1982; 138: 429-431.
Barker KA and Newburger P
Faulk Pharmaceuticals, Inc.
Rothwell Figg Ernst & Manbeck P.C.
Russel Jeffrey Edwin
LandOfFree
Targeted delivery of bioaffecting compounds for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted delivery of bioaffecting compounds for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted delivery of bioaffecting compounds for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3649045